Efficacy of early intervention on the bowel damage and intestinal surgery of Crohn's disease, based on the Lémann index

BMC Gastroenterol. 2020 Dec 11;20(1):421. doi: 10.1186/s12876-020-01575-7.

Abstract

Background: Clinicians aim to prevent progression of Crohn's disease (CD); however, many patients require surgical resection because of cumulative bowel damage. The aim of this study was to evaluate the impact of early intervention on bowel damage in patients with CD using the Lémann Index and to identify bowel resection predictors.

Methods: We analyzed consecutive patients with CD retrospectively. The Lémann Index was determined at the point of inclusion and at follow-up termination. The Paris definition was used to subdivide patients into early and late CD groups.

Results: We included 154 patients, comprising 70 with early CD and 84 with late CD. After follow-up for 17.0 months, more patients experienced a decrease in the Lémann Index (61.4% vs. 42.9%), and fewer patients showed an increase in the Lémann Index (20% vs. 35.7%) in the early compared with the late CD group. Infliximab and other therapies reversed bowel damage to a greater extent in early CD patients than in late CD patients. Twenty-two patients underwent intestinal surgery, involving 5 patients in the early CD group and 17 patients in the late CD group. Three independent predictors of bowel resection were identified: baseline Lémann index ≥ 8.99, disease behavior B1, and history of intestinal surgery.

Conclusions: Early intervention within 18 months after CD diagnosis could reverse bowel damage and decrease short-term intestinal resection. Patients with CD with a history of intestinal surgery, and/or a Lémann index > 8.99 should be treated aggressively and monitored carefully to prevent progressive bowel damage.

Keywords: Bowel damage; Early crohn’s disease; Infliximab; Intestinal surgery; Lémann index.

MeSH terms

  • Crohn Disease* / drug therapy
  • Crohn Disease* / surgery
  • Humans
  • Infliximab
  • Intestines
  • Retrospective Studies
  • Severity of Illness Index

Substances

  • Infliximab